BS_SAA624A4
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- overall_survival_months
- 70.08
- os_event
- false
- age_years
- 11.885
- sex
- M
- race
- White
- e1_e2
- E2
- umap1_2d
- -7.685332052
- umap2_2d
- -0.100695592
- umap1_3d
- 1.097368513
- umap2_3d
- 3.449384787
- umap3_3d
- 1.918782741
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.320
- KRAS_SIGNALING_DN+0.210
- SPERMATOGENESIS+0.200
- OXIDATIVE_PHOSPHORYLATION+0.190
- BILE_ACID_METABOLISM+0.110
- ALLOGRAFT_REJECTION+0.070
- COAGULATION+0.050
- MYOGENESIS-0.010
- DNA_REPAIR-0.040
- PEROXISOME-0.060
Top 10 suppressed
- G2M_CHECKPOINT-0.500
- MITOTIC_SPINDLE-0.500
- WNT_BETA_CATENIN_SIGNALING-0.500
- TGF_BETA_SIGNALING-0.460
- HEDGEHOG_SIGNALING-0.450
- NOTCH_SIGNALING-0.450
- PI3K_AKT_MTOR_SIGNALING-0.450
- ANDROGEN_RESPONSE-0.420
- MTORC1_SIGNALING-0.410
- CHOLESTEROL_HOMEOSTASIS-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_SAA624A4 | Spinal Cord Ependymoma | — | 0.953 |
| 2 | SRR1332048 | GTEX | — | 0.895 |
| 3 | MNG506 | — | — | 0.895 |
| 4 | MNG599 | — | — | 0.892 |
| 5 | MNG1296 | — | — | 0.890 |
| 6 | SRR1490465 | GTEX | — | 0.884 |
| 7 | SRR1331534 | GTEX | — | 0.882 |
| 8 | ERR4976608 | — | D | 0.881 |
| 9 | SRR8943038 | — | — | 0.875 |
| 10 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.070 | Idelalisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |